Generic drugmaker Mylan Inc. said it would buy Abbott Laboratories' specialty and branded generics business outside the United States in an all-stock transaction valued at about $5.3 billion.
Abbott will receive 105 million shares of the combined company.
© 2024 Thomson/Reuters. All rights reserved.